Teva Pharma (TEVA) Announces Generic Version of Prevacid Does Not Infringe on Patents

FREE Breaking News Alerts from StreetInsider.com!

More News related to TEVA

OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences
OncoGenex Pharmaceuticals to Present at Upcoming Investor Conferences
Morgan Stanley Downgrades Teva Pharma (TEVA) to Equalweight
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer
Clinical Data on OGX-427 Presented at the ASCO 2012 Genitourinary Cancers Symposium Provide Ongoing Evidence of Hsp27 as a Potential Therapeutic Target in Advanced Prostate Cancer

More News related to Corporate News

November 10, 2009 10:07 AM EST

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid (Lansoprazole) SoluTab. The Court found that Teva's generic lansoprazole orally disintegrating tablets do not infringe U.S. Patent No. 5,464,632. Teva intends to complete an analysis of the decision before deciding upon its next course of action.

Annual sales of the brand product were approximately $500 million in the United States for the twelve months that ended June 30, 2009 based on IMS sales data.